Good Clinical Practice: A Question & Answer Reference Guide 2018

Barnett International Publication
$79.95

 GCP18

Note: This publication will be available to ship by the second week of June. Pre-Order Now!

This industry-leading GCP reference guide answers over 1,000 of the most common and difficult questions regarding the interpretation and implementation of U.S. and international GCP standards for drugs, biologics, and medical device clinical trials. The completely updated and expanded 2018 guide includes:

  • Continued updates focused on the impact of changes to ICH GCP E6 R2, enforcement of the revisions and its impact on clinical trial processes and systems, including Quality-by-Design and Risk-based Quality Management (QM) expectations
  • Dozens of new Q&As including FDA’s guidance on R2 implementation, status of the EU Directive update, and changes to US FDA Compliance Program Guidance Manual 7348.10
  • Updates on the EU’s new General Data Protection Regulation (GDPR) and the MHRA 2018 Data Integrity Guidance
  • Coverage on updates to the “Common Rule” and NIH updates for clinical trials research
  • New questions focused specifically on how Risk-based Quality Management (Section 5 of the Addendum) impacts monitoring activities
  • Updates to state- and country-specific regulations including the US, Brazil, Argentina, Peru, India and many others
  • Over 25 contributing authors with targeted expertise in QA, Monitoring, Compliance, Site Management, the Trial Master File, Data Management and many other core clinical research areas
  • Plus extensive graphs and charts on latest inspection trends and findings!

 

Editorial Team & Expert Advisory Panel:
Editor-in-Chief: Professor Earl W. Hulihan, President, Professor Earl W. Hulihan Consultancy
Editor Emeritus: Mark Mathieu, PAREXEL International Corporation
Anne Blanchard, Blanchard & Associates, LLC (Latin America)
Nikki Christison, B.S., TIACR, CCRA, Clinical Resolutions (USA)
Tony C. Cruz, InClin, Inc. (USA) Donna W. Dorozinsky, RN, MSN, CCRC, Just In Time GCP (USA) Lourdes M. Frau MD FAAP FISPE (USA)
George Gasparis, The PEER Consulting Group (USA)
Bobby George, PhD, CCRA, Reliance Life Sciences, Pvt. Ltd. (India)
Jerold Grupp, CFR Health (USA)
Jonathan Heinemann, BioMarin Pharmaceuticals (USA)
Linda Houle, Linda Houle and Associates (Canada)
Xiaoshun Hong, Professor and Deputy Director of Information Center,
China Food and Drug Administration (China)
Professor Earl W. Hulihan, Professor Earl W. Hulihan Consultancy; Rutgers Medical School USA), China
Pharmaceutical University (Nanjing)
Allan Johansen, a3GCP Consulting (Australia and New Zealand)
Nelson Kopyt D.O., FACP, FASN, CPI, Lehigh Valley Hospital; Morsani College of Medicine;
Northeast Clinical Research Center (USA)
Susan M. Leister, MBA, PhD, CQA, CSSBB (USA)
Daniel Liu, PhD, Chief Scientific Officer, Beijing Clinical Service Center (China)
Joanne S. Malia, MS, MS, Independent GCP Consultant (USA)
Joyce Elaine Marinho, CCRP, COO, Blanchard & Associates, LLC (Latin America)
Munish Mehra, PhD, Tigermed (USA)
Mary Mills, RN, CCRA, Mary Mills and Associates, LLC (USA)
David Pfennig, MS, MBA, P-Square, LLC (USA)
Denise G. Redkar-Brown, MT., Independent Consultant (USA)
Christopher Rush, MBA, FDA Quality + Regulatory Consultants, LLC (USA)
Sandra “SAM” Sather, BSN, CCRA, CCRC, Clinical Pathways Research LLC (USA)
Chana Sternberg, Chana Sternberg Consultancy, Ltd. (Israel)
Teri Stokes, Ph.D., Cytel Inc. Clinical Research Services (USA)
Dmitry Vorobiev, MD, Ph.D., MRQA, Clinical Trials Audits and Quality Consulting (Russia)
Beat Wilder, PhD, Widler & Schiemann, (Switzerland)